公开(公告)号：US20210009700A1

公开(公告)日：2021-01-14

申请号：US16911806

申请日：2020-06-25

Applicant: Five Prime Therapeutics, Inc.

Inventor： Robert Sikorski ,  Julie Hambleton ,  Nilacantan Sankar

IPC: C07K16/28

Abstract: Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.

公开(公告)号：US20210009697A1

公开(公告)日：2021-01-14

申请号：US16646690

申请日：2018-09-12

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Katherine E. Lewis ,  Serena Kimi Perna ,  Michael Carleton ,  Ke Xu ,  Penny Phillips ,  Dimple Pandya ,  Brian Wong ,  Julie Hambleton ,  Robert Sikorski ,  Emma Masteller ,  Kevin Hestir ,  David Bellovin ,  Janine Powers ,  Ernestine Lee

IPC: C07K16/28 ,  A61K31/7068 ,  A61K31/513 ,  A61K39/395 ,  A61K31/337 ,  A61K47/69 ,  A61K47/64 ,  C12Q1/6886 ,  A61P35/00

Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

公开(公告)号：US10822421B2

公开(公告)日：2020-11-03

申请号：US16256311

申请日：2019-01-24

Applicant: Five Prime Therapeutics, Inc.

Inventor： Brian Wong ,  Emma Masteller ,  Kris Reedquist

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  A61K39/00

Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.

公开(公告)号：US20200255528A1

公开(公告)日：2020-08-13

申请号：US16814627

申请日：2020-03-10

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles KAPLAN ,  Derrick HOUSER ,  Luis BORGES ,  Gloria BRATTICH ,  David BELLOVIN ,  Felicia KEMP ,  Majid GHODDUSI ,  Nels P. NIELSON ,  Kathy MILLER ,  Maike SCHMIDT

IPC: C07K16/28 ,  G01N33/574 ,  A61P35/00

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20200055936A1

公开(公告)日：2020-02-20

申请号：US16493712

申请日：2018-03-13

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Robert J. Johnston ,  Arvind Rajpal ,  Paul O. Sheppard ,  Luis Borges ,  Andrew Rankin ,  Keith Sadoon Bahjat ,  Alan J. Korman ,  Andy X. Deng ,  Lin Hui Su ,  Ginger Rakestraw

IPC: C07K16/28

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

公开(公告)号：US20190202921A1

公开(公告)日：2019-07-04

申请号：US16243510

申请日：2019-01-09

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Brian Wong ,  Julie Hambleton ,  Robert Sikorski ,  Emma Masteller ,  Kevin Hestir ,  David Bellovin ,  Katherine E. Lewis

IPC: C07K16/28 ,  C07K16/30

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/3046 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92

Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.

公开(公告)号：US10172937B2

公开(公告)日：2019-01-08

申请号：US15166798

申请日：2016-05-27

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Harding ,  Kristen Pierce ,  Namrata Patil ,  Thomas Brennan ,  Julie Hambleton

IPC: A61K33/24 ,  A61K31/337 ,  A61K31/513 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  A61K45/06

Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.

公开(公告)号：US20180002399A1

公开(公告)日：2018-01-04

申请号：US15631180

申请日：2017-06-23

Applicant: Five Prime Therapeutics, Inc.

Inventor： Li Long ,  Thomas Brennan

IPC: C07K14/71 ,  A61K31/337 ,  A61K45/06 ,  A61K39/395 ,  A61K38/38 ,  A61K38/17 ,  A61K33/24 ,  A61K31/7048 ,  A61K31/282 ,  A61K31/555 ,  A61K31/519 ,  A61K31/513 ,  A61K31/475 ,  A61K31/4745 ,  A61K31/365 ,  A61K31/704 ,  A61K39/00

CPC classification number: C07K14/71 ,  A61K31/282 ,  A61K31/337 ,  A61K31/365 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7048 ,  A61K33/24 ,  A61K38/179 ,  A61K38/38 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/507 ,  C07K2319/30 ,  A61K2300/00

Abstract: Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.

公开(公告)号：US09765147B2

公开(公告)日：2017-09-19

申请号：US14925534

申请日：2015-10-28

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Brian Wong ,  Julie Hambleton ,  Robert Sikorski ,  Emma Masteller ,  Kevin Hestir ,  David Bellovin ,  Katherine E. Lewis

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/3046 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92

Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.

公开(公告)号：US20170152320A1

公开(公告)日：2017-06-01

申请号：US15319143

申请日：2015-06-18

Applicant: Five Prime Therapeutics, Inc.

Inventor： Julie Hambleton ,  Emma Masteller ,  James Zanghi ,  Robert Sikorski ,  Hong Xiang

IPC: C07K16/28

CPC classification number: C07K16/2866 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.